Figure 2.
Kaplan–Meier curves for (A) 1‐year progression‐free survival in erlotinib versus gefitinib and (B) 1‐year overall survival in erlotinib versus gefitinib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.